

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Cumulative incidence of common high-grade adverse events with subgroup analysis based on Carf dose and type of regimen based on selected clinical trials done in RRMM patients. See Supplementary_Table_1